Mutation profiling of circulating tumour DNA to inform prognosis and treatment selection for head and neck cancers
Dr Jenny Taylor
Length of project:
Heads Up and Oracle Cancer Trust
University of Oxford
Currently, when patients with oropharyngeal cancer are treated with chemo-radiotherapy, 12 weeks after treatment they have a PET scan to check for the presence of any remaining cancer, called residual disease.
The scan shows how successful the patients response to treatment has been. If all clear, patients can enter surveillance. If there is still tumour remaining, further treatment such as neck dissection is required.
However, for a proportion of patients, there is some doubt around what the scan is showing. Is there cancer remaining or are they clear? In these cases, even though not all these patients will have residual disease, as a precaution all patients are offered further treatment which may or may not be necessary.
On the flip side, for a minority group, patients with scans that are thought to show no residual tumour, then return at 3 months with recurrence of the disease.
Get in touch
Oracle Cancer Trust is a registered charity in England and Wales (1142037). A company limited by guarantee. Registered company in England and Wales (7125497). Registered address: Liles Morris Accountants, 1st Floor, 80 Coombe Road, New Malden KT3 4QS